Holvoet P, Perez G, Bernar H, Brouwers E, Vanloo B, Rosseneu M, Collen D
Center for Molecular and Vascular Biology, University of Leuven, Belgium.
J Clin Invest. 1994 Jan;93(1):89-98. doi: 10.1172/JCI116988.
mAb4E4, a murine monoclonal antibody that is specific for acetylated LDL and malondialdehyde-treated LDL, binds specifically to modified LDL present in human atherosclerotic lesions. It is directed against an epitope that is poorly exposed in delipidated and solubilized apolipoprotein B-100 from modified LDL. mAb4E4, as well as its F(ab')2 and Fab fragments, enhanced the uptake of both acetylated LDL and malondialdehyde-treated LDL by THP-1-derived macrophages resulting in a sixfold increase of cytoplasmic cholesteryl ester levels. The increased uptake of modified LDL/mAb4E4 complexes did not occur via the Fc receptor and did not depend on aggregation of modified LDL particles. However, their uptake was inhibited by blocking the scavenger receptors with fucoidin or by downregulation of receptor expression with endotoxins or interferon-gamma, indicating that their uptake is mediated via these receptors. Thus, generation of autoimmune antibodies against modified LDL and subsequent endocytosis of soluble modified LDL/antibody complexes via scavenger receptors may enhance foam cell generation. This mechanism may contribute to the progression of atherosclerotic lesions.
单克隆抗体4E4是一种针对乙酰化低密度脂蛋白(LDL)和丙二醛处理的LDL的鼠单克隆抗体,它能特异性结合存在于人类动脉粥样硬化病变中的修饰LDL。它针对的是一个表位,该表位在来自修饰LDL的脱脂和溶解的载脂蛋白B - 100中暴露程度较低。单克隆抗体4E4及其F(ab')2和Fab片段增强了THP - 1衍生的巨噬细胞对乙酰化LDL和丙二醛处理的LDL的摄取,导致细胞质胆固醇酯水平增加了六倍。修饰LDL/单克隆抗体4E4复合物摄取的增加并非通过Fc受体发生,也不依赖于修饰LDL颗粒的聚集。然而,用岩藻依聚糖阻断清道夫受体或用内毒素或干扰素 - γ下调受体表达可抑制它们的摄取,这表明它们的摄取是通过这些受体介导的。因此,针对修饰LDL产生自身免疫抗体以及随后通过清道夫受体对可溶性修饰LDL/抗体复合物进行内吞作用可能会增强泡沫细胞的生成。这种机制可能有助于动脉粥样硬化病变的进展。